9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...
3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...
3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...
3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...
3 May 2023 - NICE has issued evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in ...
3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after ...
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years ...
17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...
13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...
13 April 2023 - NICE working with international organisations to develop guidance. ...
11 April 2023 - The aims of this study were to review the current interactions within and across regulatory and HTA ...
12 April 2023 - The objective of this study is to assess whether conditionally approved drugs face higher probabilities of HTA ...